Stent systems developer Tryton Medical has obtained the US Food and Drug Administration (FDA) premarket approval (PMA) for its Tryton Side Branch Stent to treat coronary bifurcation lesions involving large side branches.

Equipped with the Tri-ZONE technology, Tryton Side Branch Stent system is made of cobalt chromium and is deployed in the side branch artery utilising single wire balloon-expandable stent delivery system.

Compatible with any conventional drug eluting stent in the main vessel, the device comes in different diameters such as 2.5mm to 3.5mm in the side branch.

"Interventional cardiologists now have access to a stent that is specifically engineered to provide the complete lesion coverage."

Tryton Medical president and chief executive officer Shawn McCarthy said: “With this first-of-its-kind approval in the US, interventional cardiologists now have access to a stent that is specifically engineered to provide the complete lesion coverage and more predictable patient outcomes needed for the challenging anatomy of coronary bifurcation lesions.”

A randomised investigational device exemption (IDE) clinical trial conducted to evaluate the stent indicated that it has decreased the need for additional bailout stenting, during a post hoc analysis.

The study also found that the stent led to statistically lower side branch percent diameter stenosis at nine month follow up and showed comparable major adverse cardiovascular events (MACE) and myocardial infarction (MI) rates at three years.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The firm has signed a strategic distribution agreement with Cardinal Health, under which its interventional vascular business Cordis will exclusively distribute the stent in the US

Used to treat more than 12,000 patients till date, the stent is available in several countries across Europe, the Middle East and Africa.